Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars
10 Articles
10 Articles
Biocon Biologics gets EU approval for 2 drugs to treat bone cancer, osteoporosis and bone loss
Biocon Biologics, a subsidiary of Biocon, has secured EU marketing authorisation for its Denosumab biosimilars Vevzuo and Evfraxy, expanding treatment options for cancer-related bone disease and osteoporosis across Europe.
Biocon Biologics gets EU approval for Denosumab biosimilars Vevzuo & Evfraxy, expanding access to bone disease treatments across Europe.


Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars
/PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European...
Biocon Biologics gains EU approval for bone health therapies - Pharmafile
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking a significant step in expanding patient access to critical bone health treatments across Europe. Vevzuo is approved for the prevention of skeletal complications in adults with advanced cancers involving bone, as well as for treating […] The post Biocon Biologics gains EU approval for bone heal…
Biocon Biologics Granted Marketing Authorisation By European Commission For Bone Disease Medicines
Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
To view factuality data please Upgrade to Premium